Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Former Accuri CEO to lead intravenous device start-up

This article was originally published in Clinica

  • News

Executive Summary

Tangent Medical Technologies, a development-stage company focused on next-generation intravenous access systems, has appointed Jeffrey Williams as CEO and chairman. Mr Williams was formerly president and CEO of flow cytometry specialist Accuri Cytometers until the company was sold to Becton Dickinson in March (www.clinica.co.uk, 21 March 2011). Prior to that, he was head of molecular diagnostic company HandyLab. Mr Williams succeeds Hank Brown, who was a founding investor of Ann Arbor, Michigan-based Tangent and has been leading the company since it was founded in July 2009. Tangent's lead product is the NovaCath peripheral IV system with integrated stablisation and blood containment features; the company expects to begin generating revenue from sales of the product in 2012.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT097785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By